CAR-T cell therapy for T-cell leukemia or lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new treatment made from your own immune cells, designed to target and kill cancer cells that have a protein called CD7. It might help people with T-cell leukemia or lymphoma that has returned or not responded to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have T-cell leukemia or lymphoma (T-LBL/ALL) that has come back or not responded to treatment.
- Your cancer cells must have the CD7 protein on their surface.
- You must be between 18 and 75 years old.
- You must be able to care for yourself (ECOG score 0-2) and have a life expectancy over 12 weeks.
- You cannot have had a stem cell transplant in the last 6 months or any prior CAR-T cell therapy.
- You must not have a serious active infection or ongoing graft-versus-host disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a type of immune cell therapy (CAR-T) made from your own T-cells, designed to treat T-cell lymphoma or T-cell leukemia that has come back or didn’t respond. It may help by directing your immune system to attack the cancer, and it requires specific eligibility and safety checks.
This trial tests a new treatment called CD7 CAR-T, which uses your own immune cells modified to find and attack cancer cells that have a protein called CD7 on their surface. It's for people with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma that has come back or not responded to standard treatments.
This trial tests a new type of immune cell therapy (called CAR-T) that targets two proteins, CD5 and CD7, on the surface of T-cell leukemia or lymphoma cells. It may be an option for people whose cancer came back or didn't respond to standard treatment.
This trial tests a new type of immunotherapy called anti-CD7 CAR-T cells for children and young adults with T-cell acute lymphoblastic leukemia or lymphoma that has come back or not responded to standard treatments. The goal is to see if these specially engineered immune cells can find and destroy cancer cells that carry the CD7 protein.
This trial tests a treatment that uses your own immune cells (CAR-T) engineered to find and attack CD7 on T-cell lymphoma cells, followed by a stem cell transplant to rebuild your immune system. It is for people with certain types of T-cell lymphoma that have come back or not responded to standard treatments.
This trial tests a new treatment called PA3-17, which uses your own immune cells modified to target and kill cancer cells that have a protein called CD7 on them. It is designed for patients with T-cell leukemia or lymphoma that has come back or did not respond to prior treatments.
Hear when a new T Lymphoblastic Leukemia/Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.